Research, Medical

Small Molecule Apis Made with Compelling Science

July 17, 2023

Small Molecule Apis Made
As your API demand grows, we grow with you. While we can manufacture volumes in metric tons, we can also go small. If you have a chemistry-based compound and need smaller batches for clinical or commercial use, we can offer the quantities you need at our cGMP small-scale/pilot facilities until you’re ready for full-scale manufacturing.

Spotlight

BioMarin Pharmaceutical Inc.

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored.

OTHER WHITEPAPERS
news image

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Read More
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More
news image

Three Trends to Watch in Life Sciences

whitePaper | June 10, 2022

Healthcare is changing rapidly. Companies who provide products and services to hospitals and physicians will need to adjust their operations to change.

Read More
news image

Optimizing Freeze-Thaw Processes for Cell and Gene Therapy Commercialization

whitePaper | June 23, 2022

Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.

Read More
news image

Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply

whitePaper | December 6, 2022

BioPhorum’s mission is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all.

Read More
news image

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.

Read More

Spotlight

BioMarin Pharmaceutical Inc.

BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored.

Events